Synthesis of calcium phosphate-binding liposome for drug delivery

被引:67
作者
Anada, Takahisa [1 ]
Takeda, Yoichi [2 ]
Honda, Yoshitomo [1 ]
Sakurai, Kazuo [2 ]
Suzuki, Osamu [1 ]
机构
[1] Tohoku Univ, Grad Sch Dent, Aoba Ku, Sendai, Miyagi 9808575, Japan
[2] Univ Kitakyushu, Dept Chem Proc & Environm, Wakamatsu Ku, Fukuoka 8080135, Japan
关键词
Drug delivery system; Liposome; Bone; Hydroxyapatite; MACROMOLECULAR THERAPEUTICS; BONE; AGENTS; HYDROXYAPATITE; PROTEINS;
D O I
10.1016/j.bmcl.2009.05.117
中图分类号
R914 [药物化学];
学科分类号
100705 [微生物与生化药学];
摘要
Metastatic bone disease is often associated with bone pain, pathologic fractures, and nerve compression syndromes. Effective therapies to inhibit the progression of bone metastases would have important clinical benefits. Therefore, we developed a novel calcium phosphate-binding liposome for a bone-targeting drug delivery system. We synthesized a novel amphipathic molecule bearing a bisphosphonate (BP) head group to recognize and bind to hydroxyapatite (HA). We demonstrated that the liposomes having BP moieties show high affinity for HA. Doxorubicin-loaded liposomes adsorbed on the surface of HA significantly reduce the number of viable human osteosarcoma MG63 cells. This shows that the liposomes can be excellent carriers for anticancer drugs because they specifically target bone tissue. This calcium phosphate-binding liposome system could be used with many drugs for bone-related diseases such as osteoporosis, rheumatoid arthritis, and multiple myeloma. (C) 2009 Elsevier Ltd. All rights reserved.
引用
收藏
页码:4148 / 4150
页数:3
相关论文
共 13 条
[1]
BISPHOSPHONATES - PHARMACOLOGY AND USE IN THE TREATMENT OF TUMOR-INDUCED HYPERCALCEMIC AND METASTATIC BONE-DISEASE [J].
FLEISCH, H .
DRUGS, 1991, 42 (06) :919-944
[2]
Doxorubicin induces aggregation of small negatively charged liposomes [J].
Fonseca, M ;
vanWinden, ECA ;
Crommelin, DJA .
EUROPEAN JOURNAL OF PHARMACEUTICS AND BIOPHARMACEUTICS, 1997, 43 (01) :9-17
[3]
Designing proteins for bone targeting [J].
Gittens, SA ;
Bansal, G ;
Zernicke, RF ;
Uludag, H .
ADVANCED DRUG DELIVERY REVIEWS, 2005, 57 (07) :1011-1036
[4]
Bone targeting potential of bisphosphonate-targeted liposomes - Preparation, characterization and hydroxyapatite binding in vitro [J].
Hengst, V. ;
Oussoren, C. ;
Kissel, T. ;
Storm, G. .
INTERNATIONAL JOURNAL OF PHARMACEUTICS, 2007, 331 (02) :224-227
[5]
Bone-specific drug delivery systems - Approaches via chemical modification of bone-seeking agents [J].
Hirabayashi, H ;
Fujisaki, J .
CLINICAL PHARMACOKINETICS, 2003, 42 (15) :1319-1330
[6]
MATSUMURA Y, 1986, CANCER RES, V46, P6387
[7]
UPTAKE OF ANTINEOPLASTIC AGENTS INTO LARGE UNILAMELLAR VESICLES IN RESPONSE TO A MEMBRANE-POTENTIAL [J].
MAYER, LD ;
BALLY, MB ;
HOPE, MJ ;
CULLIS, PR .
BIOCHIMICA ET BIOPHYSICA ACTA, 1985, 816 (02) :294-302
[8]
Metastasis to bone: Causes, consequences and therapeutic opportunities [J].
Mundy, GR .
NATURE REVIEWS CANCER, 2002, 2 (08) :584-593
[9]
Bisphosphonate actions: Physical chemistry revisited [J].
Papapoulos, Socrates E. .
BONE, 2006, 38 (05) :613-616
[10]
Doxorubicin-induced cardiomyopathy [J].
Singal, PK ;
Iliskovic, N .
NEW ENGLAND JOURNAL OF MEDICINE, 1998, 339 (13) :900-905